IO NewsWire

July 14, 2011 07:30 ET

Unilife Corp. Sends Out Its First Order to Sanofi

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by the IO News Wire

NEW YORK, NY--(Marketwire - Jul 14, 2011) - Unilife Corp. (NASDAQ: UNIS) announced they have begun supplying Sanofi with its Unifill® syringe as per the terms of their agreement.

Unilife has received a total of $40 million from Sanofi for the exclusivity of the Unifill syringe within the full therapeutic class of antithrombotic agents and vaccines in addition to four smaller subgroups up until June 2014.

The Unifill® ready-to-fill (prefilled) syringe is a primary drug container with passive (automatic) safety features fully integrated within the glass barrel. It is designed for integration into the fill-finish systems used for equivalent products, and supplied as per standard handling processes. The Unifill syringe is similar in size to an equivalent standard prefilled syringe and is significantly smaller than those supplied with an ancillary safety device. This sets Unilifes product aside from all others on the market.

To read more on Unilife please visit

Other active stocks are Becton, Dickinson and Co (NYSE: BDX), Thermo Fisher Scientific (NYSE: TMO) and Waters Corp (NYSE: WAT)

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.

Contact Information